Auteurs
Analysis
UK
Racine
Analysis
UK
Exploration
Accueil
Racine
Racine

Serveur d'exploration sur les relations entre la France et l'Australie - Analysis (UK)

Index « Auteurs » - entrée « R. Rosso »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
R. Rosenson < R. Rosso < R. Rossol  Facettes :

List of bibliographic references

Number of relevant bibliographic references: 2.
Ident.Authors (with country if any)Title
003552 (2002) J. Cassidy [Royaume-Uni] ; C. Twelves [Royaume-Uni] ; E. Van Cutsem [Belgique] ; P. Hoff [États-Unis] ; E. Bajetta [Italie] ; M. Boyer [Australie] ; R. Bugat [France] ; U. Burger [Suisse] ; A. Garin [Russie] ; U. Graeven [Allemagne] ; J. Mckendrick [Australie] ; J. Maroun [Canada] ; J. Marshall [États-Unis] ; B. Osterwalder [Suisse] ; G. Pe Rez-Manga [Espagne] ; R. Rosso [Italie] ; P. Rougier [France] ; R. L. Schilsky [États-Unis]First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin
003622 (2001) J. A. O'Shaughnessy [États-Unis] ; J. Blum [États-Unis] ; V. Moiseyenko ; S. E. Jones [États-Unis] ; D. Miles [Royaume-Uni] ; D. Bell [Australie] ; R. Rosso [Italie] ; L. Mauriac [France] ; B. Osterwalder [Suisse] ; H.-U. Burger [Suisse] ; S. Laws [France]Randomized, open-label, phase II trial of oral capecitabine (Xeloda®) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer

List of associated KwdEn.i

Nombre de
documents		Descripteur
2Antineoplastic agent
2Capecitabine
2Chemotherapy
2Comparative study
2Drug combination
2Fluoropyrimidine derivatives
2Fluorouracil
2Human
2Intravenous administration
2Malignant tumor
2Metastatic
2Oral administration
2Pyrimidine derivatives
2Toxicity
2Treatment
2Treatment efficiency
1Abnormality
1Advanced stage
1Adverse events
1Baseline
1Baseline capecitabine dose
1Baseline creatinine clearance
1Baseline dose
1Calcium folinate
1Capecitabine group
1Capecitabine scheme
1Clearance
1Clin oncol
1Clinical trial
1Colon
1Colorectal
1Colorectal cancer
1Creatinine
1Creatinine clearance
1Cyclophosphamide
1Disease progression
1Dose
1Dose modification
1Dose reduction
1Dose reductions
1Equivalent survival
1Equivalent time
1Favorable safety profile
1First dose modification
1Further grade
1Higher incidence
1Impairment
1Key words: capecitabine, colorectal cancer, fluoropyrimidine, tolerability
1Leucovorin
1Lower incidence
1Mammary gland
1Mayo clinic regimen
1Median
1Median duration
1Median time
1Metastatic breast cancer
1Metastatic colorectal cancer
1Methotrexate
1Modification
1Nitrogen mustard
1Oncology
1Oral capecitabine
1Oxazaphosphinane derivatives
1Pharmacokinetic
1Pharmacokinetic study
1Phase II trial
1Progression
1Randomization
1Rectum
1Regression analysis
1Renal
1Renal function
1Rest period
1Route of administration
1Safety data
1Safety population
1Safety profile
1Serum creatinine
1Stomatitis
1Subpopulation
1Syndrome
1Systemic exposure
1Treatment arms
1Treatment groups
1Treatment interruption
1Tumor tissue

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/UK/Analysis

HfdIndexSelect -h $EXPLOR_AREA/Data/UK/Analysis/Author.i -k "R. Rosso" 

HfdIndexSelect -h $EXPLOR_AREA/Data/UK/Analysis/Author.i  \
                -Sk "R. Rosso" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/UK/Analysis/biblio.hfd

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Asie
   |area=    AustralieFrV1
   |flux=    UK
   |étape=   Analysis
   |type=    indexItem
   |index=    Author.i
   |clé=    R. Rosso
}}
Wicri

This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024